Gosset Ownership
Private
Employees
~13
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Talisman Therapeutics General Information
Talisman Therapeutics has developed a proprietary iPSC-based platform for modeling neurodegenerative diseases, with a focus on Alzheimer’s. Their approach enables more relevant compound identification and de-risks drug development. Internal programs are in preclinical stages, targeting lysosome biology, pathogenic protein reduction, and microglial health. The company also partners with biotechs and pharma to support external neuroscience discovery efforts. No clinical results have been published.
Drug Pipeline
No pipeline data available
Key Partnerships
Several large pharmaceutical companies as customers/partners for R&D services, Biotechs and venture capital-backed companies for preclinical discovery support
Talisman Therapeutics Funding
No funding data available
To view Talisman Therapeutics's complete valuation and funding history, request access »